Revisiting posttransplant survival for hepatitis C virus recipients.
Hepatitis C virus (HCV) is the most frequent indication for adult liver transplantation in Europe and United States. Posttransplantation HCV recurrence is universal and previous studies have reported a reduced survival in comparison to non-HCV recipients. We report the findings of a comparative survival analysis of adult recipients (n=12,434) with HCV from two eras using the United Network for Organ Sharing database. Cox regression modeling was used to compare both eras (A: 1994-1998 and B: 1999-2003). The 1-, 3-, and 5-year adjusted graft survivals for era A (n=5,215) and era B (n=7,519) were 80%, 69%, and 62% versus 84%, 72%, and 64%, respectively (P<0.001), whereas the 1-, 3-, and 5-year adjusted patient survivals were 86%, 77%, and 70% for era A versus 87%, 78%, and 70% for era B, respectively (P=0.79). This comparative analysis of posttransplant outcomes for HCV recipients suggests an improvement in graft survival in the latter years.
Kemmer
Nyingi
N
Division of Digestive Diseases, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA. nyingi.kemmer@uc.edu
Kaiser
Tiffany E
TE
Zacharias
Victoria
V
Secic
Michelle
M
Neff
Guy W
GW
D016208:Databases, Factual; D006085:Graft Survival; D016174:Hepacivirus / Q000378:metabolism*; D006526:Hepatitis C / Q000628:therapy / Q000821:virology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008107:Liver Diseases / Q000628:therapy* / Q000821:virology*; D016031:Liver Transplantation / Q000009:adverse effects* / Q000379:methods*; D016016:Proportional Hazards Models; D013997:Time Factors; D009927:Tissue and Organ Procurement; D016896:Treatment Outcome
D007166:Immunosuppressive Agents